Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

301
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
301

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Zero-Shot to Bedside: A Practical Playbook for Adapting Open-Source Large Language Models to Clinical Symptom Extraction.

Proceedings of machine learning research·2026
Same author

Higher Medical Urgency Is Associated With Greater Psychosocial Risk Tolerance in Liver Transplant Listing and Selection.

Transplantation·2026
Same author

Access to care affects electronic health record reliability and AI-driven disease prediction.

Nature health·2026
Same author

Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.

American journal of hematology·2026
Same author

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.

Blood cancer journal·2026
Same author

Large Language Model Predicts Surgeon Recommendations for Imaging and Surgery for Patients Presenting for Knee and Shoulder Complaints With 70% and 81% Accuracy Using Previsit Questionnaire Responses.

Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association·2026

Related Experiment Video

Updated: May 12, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.2K

Investigating CAR-T Treatment Access for Multiple Myeloma Patients Using Real-World Evidence.

Jaysón Davidson1,2, Anupama Kumar3, Ayan Patel2

  • 1Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA.

Medrxiv : the Preprint Server for Health Sciences
|May 5, 2025
PubMed
Summary
This summary is machine-generated.

Black patients face significant disparities in accessing CAR-T therapy for Multiple Myeloma (MM). This study reveals race and location influence treatment access, highlighting critical inequities in care.

Keywords:
CAR-T therapyMultiple Myelomahealthcare disparitiessocial determinants of health

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.1K
Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

2.8K

Related Experiment Videos

Last Updated: May 12, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.2K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.1K
Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

2.8K

Area of Science:

  • Hematologic Malignancies
  • Cancer Therapy Access
  • Health Disparities Research

Background:

  • Multiple Myeloma (MM) disproportionately affects Black patients.
  • Current MM treatments are limited, and CAR-T therapy shows promise.
  • Existing disparities in CAR-T therapy access require investigation.

Purpose of the Study:

  • To explore disparities in Multiple Myeloma disease risk.
  • To investigate inequities in CAR-T therapy access.
  • To analyze the impact of race and healthcare location on CAR-T access.

Main Methods:

  • A cohort of 12,360 MM patients was analyzed from the UCHDW.
  • Regression models assessed factors associated with CAR-T therapy access.
  • GPT-4 analyzed clinical notes for CAR-T discussion and eligibility.

Main Results:

  • Black patients were less likely to receive CAR-T therapy (OR=0.33) compared to White patients.
  • Patients at UC-3, with a higher proportion of Black patients, had reduced CAR-T access (OR=0.42).
  • Pacific Islander patients showed the highest CAR-T eligibility rate without prior discussion.

Conclusions:

  • Race and UC-Location significantly influence CAR-T therapy access disparities in MM.
  • Addressing these inequities is crucial for equitable cancer care.
  • Further research is needed to understand and mitigate these disparities.